Traduction de «report of intervention in cardiac » (Néerlandais → Français) :

77. Stren Z et al: The rois of a hospital director in efforts to reduce infections after surgical procedures: a report of intervention in cardiac surgery.
77. Stren Z et al : The rois of a hospital director in efforts to reduce infections after surgical procédures : a report of intervention in cardiac surgery.

A RANDOMIZED CONTROL TRIAL OF AN EXTENSIVE LIFESTYLE MANAGEMENT INTERVENTION (ELMI) FOLLOWING CARDIAC REHABILITATION: STUDY OBSERVATIONS AND BASELINE DATA.
MANAGEMENT INTERVENTION (ELMI) FOLLOWING CARDIAC REHABILITATION : STUDY OBSERVATIONS AND BASELINE DATA.

In 1999 zijn in de Lancet de resultaten gepubliceerd van twee grootschalige gerandomiseerde dubbelblinde studies waarin het effect van twee cardioselectieve β-blokkers op de mortaliteit bij patiënten met hartfalen werd onderzocht: de CIBIS-II-studie (Cardiac Insufficiency Bisoprolol Study II) en de MERIT-HF-studie (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure).
Le Lancet a publié en 1999 les résultats de deux grandes études randomisées en double aveugle: l' étude CIBIS-II (Cardiac Insufficiency Bisoprolol Study II) et l' étude MERIT-HF (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure) qui traitent de l' effet de deux β-bloquants cardiosélectifs sur la mortalité dans l' insuffisance cardiaque.

In de Lescol Intervention Prevention Study (LIPS) werd het effect van fluvastatine op ernstige ongewenste cardiale voorvallen (MACE - major adverse cardiac events, d.w.z. cardiaal overlijden, nietfataal myocardinfarct en coronaire revascularisatie) geëvalueerd bij patiënten met coronair hartlijden die eerder een succesvolle percutane coronaire interventie hadden ondergaan.
Au cours de l’étude LIPS (Lescol Intervention Prevention Study, Etude Prévention Intervention Lescol), l’effet de la fluvastatine sur les effets indésirables cardiaques majeurs (EICM, c.-à-d. décès d’origine cardiaque, infarctus du myocarde non fatal et revascularisation coronaire) a été évalué chez des patients atteints d’une cardiopathie ischémique ayant d’abord subi avec succès une intervention coronaire percutanée.

In this scientific advisory report, the Superior Health Council provides an expert opinion on screening for cardiac abnormalities that predispose to
In this scientific advisory report, the Superior Health Council provides an expert opinion on screening for cardiac abnormalities that predispose to sudden cardiac death among the adolescents and young adults

De interventies moeten altijd geregistreerd worden in de toepassing van de BWGIC (Belgian Working Group on Interventional Cardiology) en het gestandaardiseerd registratieformulier (clinical data report), beschikbaar via de toepassing, moet afgedrukt worden.
Les interventions doivent toujours être encodées dans l’application du BWGIC (Belgian Working Group on Interventional Cardiology) et le formulaire d’enregistrement standardisé (clinical data report), reçu de l’application, devra être imprimé.

Het volledig ingevuld gestandaardiseerd registratieformulier (clinical data report) van het dilatatiemateriaal en de coronaire stents wordt door de implanterend geneesheer-specialist aan de adviserend geneesheer van de verzekeringsinstelling ter kennisgeving meegedeeld en aan de « Belgian Working Group on Interventional Cardiology » bezorgd.
Le formulaire d’enregistrement standardisé (clinical data report), dûment complété, du matériel de dilatation et des tuteurs coronaires est transmis par le médecin-spécialiste implanteur pour notification au médecin conseil de l’organisme assureur et est transmis au « Belgian Working Group on Interventional Cardiology ».

Intervention When a MRSA colonised or infected patient leaves the hospital to receive ambulatory care, it is recommended that the general practitioner be fully informed of the follow-up of MRSA colonisation or infection through the discharge medical report and any additional standard document Patients recently hospitalised for more than 24 hours or transferred from another hospital or presenting risk factors for MRSA colonisation must be isolated.
Quand le patient colonisé ou infecté par MRSA quitte l’hôpital pour recevoir des soins ambulatoires, il est conseillé d’informer de manière complète le médecin généraliste du suivi de la colonisation ou de l’infection à MRSA au moyen du rapport médical de renvoi ou de tout document standard supplémentaire.

In this science - policy advisory report, the Belgian Superior Health Council provides recommendations regarding infection control (Aspergillus and other mould, Legionella, etc) throughout a hospital design and construction project, as well as renovation works and other technical interventions carried out in health facilities; these recommendations are intended for the internal and external players involved in these activities.
In this science - policy advisory report, the Belgian Superior Health Council provides recommendations regarding infection control (Aspergillus and other mould, Legionella, etc) throughout a hospital design and construction project, as well as renovation works and other

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.